



Additional information

- For calculating intervals between doses, 4 weeks = 28 days. Intervals of ≥ 4 months are determined by calendar months.
- Within a number range (eg, 12–18), a dash (–) should be read as “through.”
- Vaccine doses administered ≤ 4 days before the minimum age or interval are considered valid. Doses of any vaccine administered ≥ 5 days earlier than the minimum age or minimum interval should not be counted as valid and should be repeated as age appropriate. **The repeat dose should be spaced after the invalid dose by the recommended minimum interval.** For further details, see <https://publications.aap.org/redbook/book/755/chapter/14074243/Immunization-Schedule-and-Timing-of-Vaccines>.
- Information on travel vaccination requirements and recommendations is available at <https://publications.aap.org/redbook/book/755/chapter/14074567/International-Travel>.
- For vaccination of persons with immunodeficiencies, see <https://publications.aap.org/redbook/book/755/chapter/14074446/Immunization-and-Other-Considerations-in>.
- For information about vaccination in the setting of a vaccine-preventable disease outbreak, contact your state or local health department.
- The National Vaccine Injury Compensation Program (VICP) is a no-fault alternative to the traditional legal system for resolving vaccine injury claims. All vaccines included in the child and adolescent vaccine schedule are covered by VICP except dengue, PPSV23, RSV, Mpox and COVID-19 vaccines. Mpox and COVID-19 vaccines are covered by the Countermeasures Injury Compensation Program (CICP). For more information, see www.hrsa.gov/vaccinecompensation (Accessed August 11, 2025) or www.hrsa.gov/cicp (Accessed August 11, 2025).

COVID-19 vaccination

(minimum age: 6 months [Moderna Spikevax], 5 years [Pfizer-BioNTech Comirnaty], 12 years [Novavax Nuvaxovid, Moderna mNEXSPIKE])

Refer to the AAP's COVID-19 Vaccine Dosing for a visual quick reference guide, www.aap.org/CovidVaccineGuide.

Trade names are used for Moderna because there is more than 1 Moderna product available.

Routine vaccination

Everyone age 6–23 months

- **Unvaccinated** (ie, never received any COVID-19 vaccine doses):
 - 2 doses Moderna Spikevax 0, 4–8 weeks
- **Incomplete initial vaccination series:**
 - **1 dose Moderna:** complete initial series with 1 dose 4–8 weeks after most recent dose of Spikevax
 - **1 dose Pfizer-BioNTech:** complete initial series with 2 doses Moderna Spikevax 8 weeks apart (administer dose 1 4–8 weeks after most recent dose)
 - **2 doses Pfizer-BioNTech:** complete initial series with 1 dose Moderna Spikevax at least 8 weeks after the most recent dose
- **Completed initial vaccination series:**
 - **1 dose Moderna Spikevax** at least 8 weeks after the most recent dose

Special situations

Age 2–18 years in the following risk groups*: persons at high risk of severe COVID-19, residents of long-term care facilities or other congregate settings, persons who have never been vaccinated against COVID-19, persons whose household contacts are at high risk for severe COVID-19

- **Ages 2–4 years:** 1 dose of Moderna Spikevax regardless of previous vaccination status at least 8 weeks after the most recent dose
- **Ages 5–11 years:** 1 dose of Moderna Spikevax or Pfizer-BioNTech Comirnaty regardless of previous vaccination status at least 8 weeks after the most recent dose
- **Ages 12–18 years:**
 - 1 dose of Moderna Spikevax, Pfizer-BioNTech Comirnaty, or Novavax Nuvaxovid regardless of previous vaccination status at least 8 weeks after the most recent dose
 - 1 dose of Moderna mNEXSPIKE regardless of previous vaccination status at least 12 weeks after the last dose was received

Children 2 through 18 years of age not included in the risk groups above whose parent or guardian desires their protection from COVID-19 should be offered a single dose of age-appropriate COVID-19 vaccine.

Use any available COVID-19 vaccine appropriate by age and health status that is approved by the FDA through a biologics license application. The most updated version of the COVID-19 vaccine that is available should be used.

*Refer to the AAP's COVID-19 Vaccine Policy Statement for more information on risk groups, <https://doi.org/10.1542/peds.2025-073924>.

Persons who are moderately or severely immunocompromised.

People eligible for additional doses include those who are receiving active cancer treatment for tumors or cancers of the blood, those who received an organ transplant and are taking medicine to suppress the immune system, those who received a hematopoietic cell transplant within the last 2 years or are taking medicine to suppress the immune system, those with moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome), those with advanced or untreated HIV infection, and those with active treatment with high-dose corticosteroids or other drugs that may suppress an immune response. For revaccination guidance for children with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy, refer to: <https://doi.org/10.1111/tid.14109>.

Age 6 months–4 years moderately or severely immunocompromised

- **Unvaccinated:**
 - 4 doses (**3-dose initial series Moderna Spikevax** at 0, 4 weeks, and at least 4 weeks after dose 2, followed by 1 dose Moderna Spikevax 6 months later [minimum interval 2 months]). May administer additional doses.**
- **Incomplete initial 3-dose vaccination series:**
 - **Previous vaccination with Moderna**
 - **1 dose Moderna:** complete initial series with 2 doses Moderna Spikevax at least 4 weeks apart (administer dose 1 Moderna Spikevax 4 weeks after most recent dose), followed by 1 dose Moderna Spikevax 6 months later (minimum interval 2 months). May administer additional doses of Moderna Spikevax.**
 - **2 doses Moderna:** complete initial series with 1 dose Moderna Spikevax at least 4 weeks after most recent dose, followed by 1 dose Moderna Spikevax 6 months later (minimum interval 2 months). May administer additional doses of Moderna Spikevax.**